Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 3,233 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,233 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $55.87, for a total transaction of $180,627.71. Following the sale, the insider now directly owns 153,194 shares of the company's stock, valued at $8,558,948.78. This represents a 2.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 28th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.19, for a total transaction of $97,694.84.
• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92.
• On Monday, March 3rd, Soleil Boughton sold 4,151 shares of Hims & Hers Health stock. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72.

Hims & Hers Health Stock Up 8.3%

Shares of NYSE HIMS traded up $4.34 during mid-day trading on Friday, reaching $56.74. 40,946,855 shares of the company were exchanged, compared to its average volume of 19,737,944. The company's 50-day simple moving average is $39.45 and its 200-day simple moving average is $35.80. The stock has a market capitalization of $12.70 billion, a P/E ratio of 128.96 and a beta of 1.84. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's quarterly revenue was up 110.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.05 EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Morgan Stanley cut their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Bank of America increased their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $37.67.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the period. Farallon Capital Management LLC increased its position in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC increased its position in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.